Comparative Pharmacology
Head-to-head clinical analysis: LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus OGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus OGEN.
LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE vs OGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive. Ethinyl estradiol and levonorgestrel inhibit gonadotropin release (FSH, LH), suppressing ovulation. Progestin effect: thickens cervical mucus, alters endometrial receptivity. Ferrous fumarate provides iron supplementation during placebo phase.
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription leading to cell proliferation and differentiation in target tissues.
One tablet (0.15 mg levonorgestrel, 0.03 mg ethinyl estradiol, 75 mg ferrous fumarate) orally once daily at the same time for 21 consecutive days, followed by one ferrous fumarate-only tablet (75 mg) orally once daily for 7 days (28-day cycle).
0.75 mg orally once daily, cyclically (3 weeks on, 1 week off) for moderate to severe vasomotor symptoms associated with menopause.
None Documented
None Documented
Levonorgestrel: ~25 hours, steady-state after 5 days. Ethinyl estradiol: ~13 hours (7–20). Ferrous fumarate: not applicable.
Terminal elimination half-life of estrone is approximately 10-24 hours (mean ~14 hours); clinical context: permits once-daily dosing.
Levonorgestrel: ~45% renal, ~32% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Ferrous fumarate: iron excreted in feces as unabsorbed; minimal renal.
Renal elimination of conjugated metabolites (estrone sulfate, estradiol glucuronide) accounts for >95% of excretion; fecal elimination is <5%.
Category D/X
Category C
Estrogen
Estrogen